Other Events ·
Annovis Bio stockholders approve doubling authorized common shares to 140 million
ANVSAnnovis Bio, Inc.
At a Special Meeting of Stockholders held on November 3, 2026, Annovis Bio, Inc. shareholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 70,000,000 to 140,000,000. The proposal received approximately 85.6% of votes cast. Additionally, shareholders ratified an amendment to the 2019 Equity Incentive Plan to increase authorized shares under the plan. The Charter Amendment was filed with the Secretary of State of Delaware on November 4, 2026. Annovis Bio is a clinical-stage biotechnology company focused on developing therapies for rare diseases.